Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... rates of DES's in patients with and without diabetes in a real-world setting. The article reported ... no increased risk of restenosis for patients with diabetes as compared to those without diabetes. Data for ... restenosis was 1.23 times higher in patients with diabetes than in patients without diabetes. In patients ...

Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections

... received from people living with diabetes, diabetes educators, physicians and hospital nurses, we ... Advance(TM) we can offer more people with diabetes access to a user-friendly and safe device ... be unveiled at the annual American Association of diabetes Educators Conference in Atlanta, Georgia August ...

Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

... first clinical trial on patients with Type 1 diabetes Mellitus, whereas, all Oramed's trials up to date ... and was effective on patients with type 1 diabetes when taken prior to a meal." Currently, ... is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... M.D., vice president, corporate development, diabetes and obesity at Amylin Pharmaceuticals. "Our ... approximately two-thirds of patients with type 2 diabetes are overweight or obese, with a BMI less than 35 ... with BMI less than 35 kg/m2 without type 2 diabetes have dyslipidemia and/or hypertension. ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... Hurlbut-Johnson Distinguished Professor in diabetes Research, is professor of Medicine and associate director for research at the diabetes Center at UCSF. The main focus of his lab is to ... on Developmental and Stem Cell Biology at Joslin diabetes Center and the Department of Stem Cell and ...

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

... sustained release medication for type 2 diabetes that is injected subcutaneously and administered ... many countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic control ... unmet need for treating patients with type 2 diabetes with just one dose per week." ...

Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials

... IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) ... improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety ...

Spherix Announces Termination of Arla License Agreement

... SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and ... investigating Naturlose as a treatment for Type 2 diabetes in a Phase 3 clinical trial. The company expects ... any restriction on usages. About Type 2 diabetes Type ...

Spherix Announces Full-Scale Production of Pharmaceutical Tagatose

... Current Phase 3 Trial of Naturlose(R) for Type 2 diabetes BETHESDA, Md., June 23 ... SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and ... any restriction on usages. About Type 2 diabetes Type ...

Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit

... Barriers to Care and the Threatening Impact of diabetes in America WASHINGTON, June 12 ... solutions to address the exponential growth of diabetes in America. The universal theme from the ... including Larry Hausner, CEO of the American diabetes Association (ADA), was that the cost of the ...

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

... of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American diabetes Association in New Orleans, LA (June 5-9, 2009). ... course of ITCA 650 treatment among 44 type 2 diabetes patients (10-12 patients/dose arm) on a stable ...

Diamyd(R) Phase III Study Approved for Younger Patients in the US

... (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R). (Logo: ... years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new ...

VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation

... at the 69th Scientific Sessions of the American diabetes Association June 6, 2009 in New Orleans, LA. The ... triglyceride levels, making them more prone to diabetes and its associated metabolic complications. DGAT1 ... may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify ...

Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting

... therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa ... the 69th Scientific Sessions of the American diabetes Association (ADA), being held from June 5-9, 2009 ... loss with Qnexa stops the progression of type 2 diabetes in obese, non-diabetic patients. The results of ...

Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better

... People with diabetes can improve their general health and self-care ... against diabetes. As the world leader in diabetes diagnostics, Roche is rolling out the ACCU-CHEK ... to help adults, children and teens manage their diabetes more easily and more effectively. The initiative ...

Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management

... decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance ... its clinical proof-of-concept for the Type 2 diabetes monotherapy indication- and other projects from ... who previously led the Merck Serono diabetes franchise from Research to Clinical & ...

Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

... delivery of exenatide for the treatment of type 2 diabetes HAYWARD, Calif., May 27 /PRNewswire/ -- ... of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American diabetes Association in New Orleans, LA (June 5-9, 2009). ...

Amylin Responds to Eastbourne Letter

... the best combination of biopharmaceutical, diabetes and sales and marketing experience to achieve a ... has the potential to transform the treatment of diabetes through its efficacy and convenient once-weekly ... to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San ...

Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes

... commitment to tackle the growing epidemic of diabetes by its Behavior Change through Patient Engagement ... effective self-care. "As the world leader in diabetes diagnostics, we have a responsibility to provide solutions that overcome a critical gap in diabetes management," said Head of ...

Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes

... sustained release medication for type 2 diabetes that is injected subcutaneously and administered ... many countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic control ... for evaluating cardiovascular risk in type 2 diabetes agents. Components of the submission ...

Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market

... announced a new approach to sales within the diabetes market. Amylin's existing primary care and ... current and future portfolio of first-in-class diabetes products. The changes to Amylin's field sales ... physicians that treat significant numbers of diabetes patients. Lilly will continue their efforts ...

Metabolex Announces Election of Kurt von Emster to Board of Directors

... proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that ... Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product ...

The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers

... impact." Estimates indicate people with diabetes have about a 25-percent lifetime risk for ... and are conducting research in the areas of diabetes and prevention of limb amputations resulting from ... transplantation and co-director of the Arizona diabetes Center at the UA. The UA is collaborating ...

Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments

... to revolutionize the treatment of type 2 diabetes and will be a critical driver of future growth ... weekly as compared to two commonly prescribed diabetes medications, Januvia(TM) (sitagliptin) and ... to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San ...

Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech

... Epinex Test Could Transform diabetes Care IRVINE, Calif., March 26 /PRNewswire/ ... presented Epinex with its prestigious global diabetes research award. The award was given in recognition of Epinex's innovative G1A(TM) Rapid diabetes Monitoring Index Test , which uses glycated ...

Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events

... for evaluating cardiovascular risk in type 2 diabetes agents. Results of this analysis indicate that ... study led by two academic research centers, The diabetes Trial Unit at the Oxford Centre for diabetes (Oxford, England) and Duke Clinical Research ...

Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes

... Clinical Gold Standard Status for Type 2 diabetes in 2012, According to a New Report from Decision ... would earn a 33 percent patient share in type 2 diabetes in the United States and a 30 percent patient ... proprietary clinical gold standard for type 2 diabetes was Byetta (exenatide), owing to its efficacy and ...

MannKind Submits NDA for AFRESA for Treatment of Diabetes

... for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia. ... or 8% of the population, who have diabetes. diabetes currently affects 246 million people worldwide ... Each year, a further 7 million people develop diabetes and 3.8 million people succumb to the disease. ...

Can Obama Plan Tackle Diabetes Crisis? Epinex Test Could Help

... IRVINE, Calif., March 10 /PRNewswire/ -- diabetes will be a huge burden on President Obama's $634 ... in Irvine, California, has developed a new diabetes monitoring device that could relieve the burden of diabetes on our healthcare system. (Photo: ...

Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test

... in the assessment of risk for heart disease, diabetes and other cardiovascular diseases. The new, ... -- would be very high risk. ApoAI and diabetes The apoB/apoAI ratio is significantly higher ... to diabetes. In the Collaborative Atorvastatin diabetes (CARDS) study of diabetic patients, the ...

Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe

... begun enrollment of new onset autoimmune type 1 diabetes patients in Europe. In DEFEND, preserving beta ... of innovative immune intervention for type 1 diabetes patients. We have begun dosing otelixizumab in ... function and offer people with autoimmune type 1 diabetes improved disease control" said Dr. Louis Vaickus, ...

FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen

... Insulin Delivery Device to Help Patients with diabetes Improve Glycemic Control BRIDGEWATER, N.J., ... and children (4 years and older) with type 1 diabetes or adults with type 2 diabetes. The approval ... origin] injection) in 2007. People living with diabetes who use both Lantus(R) and Apidra(R) to help ...

Calvert Research and CureDM Sign Collaborative Agreement

... targeted for the treatment of type 1 and 2 diabetes patients. Cary, NC ... (HIP) targeted for the treatment of type 1 and 2 diabetes patients. HIP has a novel mechanism of action ... of action and suggest an exciting new target for diabetes treatment complementary to current ...

VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs

... levels of triglycerides are associated with diabetes and cardiovascular disease. These results suggest ... consensus guidelines issued by the American diabetes Association and American College of Cardiology. ... parameters considered necessary by the American diabetes Association and American College of Cardiology ...

Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research

... will help Spring Point Project and the Schulze diabetes Institute of the University of Minnesota ... superior donors of pancreatic islet tissue for diabetes cure. GeneSeek will take samples from Spring ... operates a biosecure facility, known as the diabetes Research and Wellness Foundation (DRWF) Islet ...

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

... if therapy is stopped. High blood sugar and diabetes have been reported with RISPERDAL(R) CONSTA(R) ... medications. If the person being treated has diabetes or risk factors such as being overweight or a ... with RISPERDAL(R) CONSTA(R). Complications of diabetes can be serious and even life threatening. If ...

Novel Diabetes Drug Discovery Has Potential to Reverse Disease

... Officer of CureDM. The incidence of diabetes continues to grow at a double-digit rate ... to maintaining normal glucose regulation. Current diabetes therapies, including insulin, help to control the ... the underlying mechanism of the pathology of diabetes and represents a potentially curative approach to ...

Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer

... was Vice President of Global Brand Development diabetes and Endocrine Platform Team Leader at Eli Lilly ... Previously, Mr. Mihalik was Business Unit Head of diabetes Care for Lilly U.S., where he was responsible for ... Mr. Mihalik has extensive previous experience in diabetes and has a successful track record in leadership ...

ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication

... adjudication of cardiovascular events in diabetes studies. The evaluation of cardiovascular ... infarction and stroke. FDA guidance applies to diabetes drugs evaluated in all Phase II and Phase III ... comply with the recent FDA guidelines for diabetes trials. It also provides significant savings in ...

Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study

... Established for DNA-Guided Decision Support in diabetes Drug Therapy HARTFORD, Conn., Jan. 21 ... study, co-authored with investigators from Joslin diabetes Center Affiliate at The Hospital of Central ... pharmacotherapy. TZDs are powerful diabetes drugs currently utilized in patients failing ...